Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | AGMT MM 01: the oral microbiome as a predictor of PFS in R/R myeloma

Heinz Ludwig • 2 Jun 2020
EHA 2020
Multiple Myeloma Dexamethasone Ixazomib Thalidomide
AGMT MM 01

Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, discusses the AGMT MM 01 trial (NCT02410694), which investigated the oral microbiome in patients with relapsed/refractory multiple myeloma treated with ixazomib, thalidomide and dexamethasone. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Heinz Ludwig

Identifying high-risk multiple myeloma & improving treatment strategies in this patient population
Identifying high-risk multiple myeloma & improving treatment strategies in this patient population
Heinz Ludwig • 15 Sep 2022
Factors affecting renal response in myeloma with acute renal failure due to cast nephropathy
5:06
Factors affecting renal response in myeloma with acute renal failure due to cast nephropathy
Heinz Ludwig • 20 Nov 2024
The changing approach to infection management with the influx of novel immunotherapies in myeloma
5:44
The changing approach to infection management with the influx of novel immunotherapies in myeloma
Heinz Ludwig • 20 Nov 2024
The complexities of selecting patients with smoldering myeloma for therapeutic intervention
4:35
The complexities of selecting patients with smoldering myeloma for therapeutic intervention
Heinz Ludwig • 20 Nov 2024

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Heinz Ludwig • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Heinz Ludwig • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Heinz Ludwig • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Heinz Ludwig • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals